{"article": [{"url": "https://www.marketwatch.com/story/generation-bio-upsizes-planned-ipo-and-raises-price-range-2020-06-11", "published": 1591858640.0, "headline": "Generation Bio upsizes planned IPO and raises price range", "body": "Generation Bio Inc., a biotech that specializes in gene therapy treatments for rare diseases, upsized its planned initial public offering on Thursday and raised the price range, suggesting strong demand for the deal. The company is now planning to offer 10 million shares priced at $18 to $19 each. That compares with previous plans to offer 7.4 million shares priced at $16 to $18 each. The company has applied to list on Nasdaq, under the ticker symbol \"GBIO.\" J.P. Morgan, Jefferies, Cowen and Wedbush PacGrow are underwriting the deal. Proceeds will be used to fund R&D, to develop platform technologies and for general corporate purposes. \"We are an innovative genetic medicines company creating a new class of gene therapy utilizing our proprietary non-viral gene therapy platform to provide durable, redosable treatments for millions of patients living with rare and prevalent diseases,\" the company says in its prospectus."}]}